Recent Updates
Recently added Catalysts
CING Neutral Sentiment Score: 55/100

Cingulate Announces Adjournment of Special Meeting

Friday, August 23, 2024 2 min read
Key Takeaway: Cingulate Inc. has adjourned its Special Meeting of Stockholders due to insufficient quorum for voting on proposals. The Board of Directors supports the proposals and encourages stockholders to participate in the adjourned meeting scheduled for August 28, 2024. The company employs a proprietary drug delivery technology aimed at improving treatment outcomes, particularly for ADHD, and is exploring additional therapeutic areas.

Market Sentiment Analysis

POSITIVE FACTORS

  • Cingulate has adjourned the Special Meeting to allow more time for stockholder participation.
  • The Board believes all proposals are advisable and beneficial for stockholders.
  • The company continues to advance its pipeline with innovative PTR technology.

Full Press Release Details

KANSAS CITY, Kan., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), (“Cingulate” or the “Company”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has adjourned its Special Meeting of Stockholders (the “Special Meeting”) in order to provide stockholders additional time within which to vote on all proposals.
At this time, there are not present, by remote communication or by proxy, a sufficient number of shares of the Company’s common stock to constitute a quorum. The Company’s Board of Directors continues to believe that that all of the proposals contained in the proxy statement are advisable and in the best interests of the Company’s stockholders to consider and act upon. Therefore, the Company adjourned the Special Meeting.
The adjourned meeting will be held at 11:00 a.m. Central Time on August 28, 2024, at the following url: www.meetnow.global/MCZZ4DG. The record date for the Special Meeting is June 28, 2024.
Special Meeting of Stockholders of Cingulate Inc.
The adjourned meeting will be held at 11:00 a.m. Central Time on August 28, 2024, at the following url: www.meetnow.global/MCZZ4DG. The Board of Directors unanimously recommends that stockholders vote FOR all proposals on the agenda.
Stockholders may cast their vote live by calling toll free at 1-800-652-8683 or online by going to www.envisionreports.com/CING-SP.
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of attention deficit/hyperactivity disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.
Cingulate is headquartered in Kansas City.
Vice President, Investor & Public Relations, Cingulate
TDalton@cingulate.com

Tags

Precision Timed Release™
drug delivery platform

Frequently Asked Questions

Why was the Special Meeting of Stockholders adjourned?

The meeting was adjourned due to insufficient shares present for a quorum.

When will the adjourned Special Meeting take place?

The adjourned meeting is scheduled for August 28, 2024, at 11:00 a.m. CT.

How can stockholders vote on the proposals?

Stockholders can vote live by phone or online via specific URLs provided.

What technology does Cingulate Inc. use?

Cingulate Inc. uses its proprietary Precision Timed Release™ (PTR™) technology.

What conditions is Cingulate focusing on treating?

Cingulate initially focuses on ADHD and is exploring treatments for anxiety disorders.

Tags: CING Viatris Investor Conferences Healthcare Cingulate special meeting stockholders ADHD
Last updated: Aug 23, 2024